Demaphar SRL
2.0 FTEThe score of Demaphar shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +8 % Total assets +9 % Headcount (avg FTE) 0 %
Accounts of the company itself (not consolidated).
The full file covers 13 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Demaphar's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 21,018 € | ||||
| Equity | 875,529 € | ||||
| Cash | 8,515 € | ||||
| EBITDA | 24,448 € | ||||
| Total assets | 965,578 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 12 May 2026
- Year ended 31 Dec 2024filed on 16 Jun 2025
- Year ended 31 Dec 2023filed on 11 Jun 2024
- Year ended 31 Dec 2022filed on 09 Jun 2023
- Year ended 31 Dec 2021filed on 07 Jun 2022
Demaphar's financial analysis
- Solvency90.7%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Demaphar
Demaphar's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0433.580.102
- VAT number
- BE0433580102
- Peppol
- Registered · 0208:0433580102 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 09 Mar 1988
- Registered office
- 7033 Mons
- Size
- Micro · 2.0 FTE
- Latest accounts
- 2025 · filed on 12 May 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Demaphar (SRL) has been based in Mons since 1988, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 21,018 € and equity of 875,529 €; its revenue is not published. With 2.0 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 90.7%, above the median of its sector (41.5%).
Companies similar to Demaphar
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie DE Neef - Duez Retail sale of pharmaceutical products Mons · balance sheet 181,026 €
- Akaption Retail sale of pharmaceutical products Braives · balance sheet 967,311 €
- Demuphar Retail sale of pharmaceutical products Ghent · balance sheet 978,525 €
- D'Haen Pharma Retail sale of pharmaceutical products Zottegem · balance sheet 987,565 €
- Cassifarma Retail sale of pharmaceutical products Leuven · balance sheet 942,826 €
- G-PAS Holding Retail sale of pharmaceutical products Brasschaat · balance sheet 992,375 €
- Cosom Retail sale of pharmaceutical products Genappe · balance sheet 931,343 €
- PharmaLEDA Retail sale of pharmaceutical products Ixelles · balance sheet €1.01m
Frequently asked questions about Demaphar
What is the revenue of Demaphar?
Demaphar files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Demaphar?
In Belgium, the VAT number is the company number prefixed with BE: BE0433580102 for Demaphar, if the company is VAT-registered. Its company number (CBE) is 0433.580.102.
Where is the registered office of Demaphar?
According to the CBE register, the registered office of Demaphar is in 7033 Mons.
What is the equity of Demaphar?
At the close of the 2025 financial year, the equity of Demaphar amounts to 875,529 €, a solvency of 90.7% of total assets.
How many people work at Demaphar?
2.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Demaphar?
The register lists 5 active mandates at Demaphar. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Demaphar
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →